Otsuka Holdings Company ADR (OP: OTSKY )

20.40 +0.37 (+1.85%)

Streaming Delayed Price Updated: 12:01 PM EDT, Apr 26, 2024 Add to My Watchlist

Price and Volume

Volume	18,048
Open	20.35
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	20.03
Today's Range	20.25 - 20.45
52wk Range	16.04 - 21.34
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation

April 16, 2024

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

Via Benzinga

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo

March 20, 2024

IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed.

Via Benzinga

Performance

YTD	+9.56%	+9.56%
1 Month	-1.69%	-1.69%
3 Month	+5.32%	+5.32%
6 Month	+24.62%	+24.62%
1 Year	+20.71%	+20.71%

More News

Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension

August 24, 2023

Via Benzinga

Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device

August 23, 2023

Via Benzinga

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study

August 05, 2022

Via Benzinga

Why Are Akebia Therapeutics Shares Falling Today?

May 16, 2022

Via Benzinga

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

March 30, 2022

Via Benzinga

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

May 11, 2023

Via Benzinga

Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches

November 03, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

July 01, 2022

Via Benzinga

Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?

January 31, 2022

Via Talk Markets

4 Pre-Merger SPACs to Buy That Are Poised to Soar

November 16, 2021

Via InvestorPlace

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia

June 01, 2021

Via Benzinga

3 Cheap Pharmaceutical Stocks to Grab Now

May 28, 2021

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.